Drug Trial Radar · NCT03425643
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
797
Actual
Start
Apr 24, 2018
Primary completion
Jul 10, 2023
Study completion Oct 15, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery \[neoadjuvant phase\], followed by pembrolizumab alone after surgery \[adjuvant phase\] in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will improve: 1) event free survival (EFS) by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); and 2) overall survival (OS).
Conditions
- Non-small Cell Lung Cancer
Interventions
PembrolizumabBiological
200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
PlaceboDrug
Normal saline by IV infusion Q3W, given on cycle day 1.
CisplatinDrug
75 mg/m\^2 by IV infusion Q3W, given on cycle day 1.
GemcitabineDrug
1000 mg/m\^2 by IV infusion Q3W, given on cycle days 1 and 8. Given only to participants with squamous NSCLC.
PemetrexedDrug
500 mg/m\^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event Free Survival (EFS)Time frame: Up to approximately 5 years
- Overall Survival (OS)Time frame: Up to approximately 5 years
Locations
227 sites in 25 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center ( Site 0028)
Gilbert, Arizona
Western Regional Medical Center, Inc. ( Site 0050)
Goodyear, Arizona
University of Arizona Cancer Center - Dignity Health ( Site 0062)
Phoenix, Arizona
University of Arizona Cancer Center ( Site 0012)
Tucson, Arizona
Pacific Cancer Medical Center, Inc. ( Site 0004)
Anaheim, California
Providence Saint Joseph Medical Center ( Site 0061)
Burbank, California
Pacific Cancer Care ( Site 0035)
Monterey, California
John Wayne Cancer Institute ( Site 0049)
Santa Monica, California
St Joseph Heritage Healthcare ( Site 0040)
Santa Rosa, California
Stanford University, Stanford Cancer Center ( Site 0046)
Stanford, California
Hartford Hospital ( Site 0069)
Hartford, Connecticut
Helen F. Graham Cancer Center & Research Institute ( Site 0015)
Newark, Delaware
Mayo Clinic Jacksonville ( Site 0022)
Jacksonville, Florida
Miami Cancer Institute-Baptist Hospital ( Site 0068)
Miami, Florida
Southeastern Regional Medical Center ( Site 0051)
Newnan, Georgia
Northwest Oncology and Hematology ( Site 0001)
Elk Grove Village, Illinois
Ingalls Memorial Hospital ( Site 0044)
Harvey, Illinois
PPG-Oncology ( Site 0043)
Fort Wayne, Indiana
University of Iowa Hospital and Clinics ( Site 0010)
Iowa City, Iowa
Ashland-Bellefonte Cancer Center ( Site 0021)
Ashland, Kentucky
Harry & Jeanette Weinberg Cancer Institute ( Site 0081)
Baltimore, Maryland
Boston Medical Center ( Site 0057)
Boston, Massachusetts
UMass Memorial Medical Center ( Site 0030)
Worcester, Massachusetts
Henry Ford Health System ( Site 0031)
Detroit, Michigan
Herbert Herman Cancer Center, Sparrow Hospital ( Site 0034)
Lansing, Michigan
Mayo Clinic ( Site 0026)
Rochester, Minnesota
St. Vincent Healthcare Frontier Cancer Center ( Site 0005)
Billings, Montana
University of Nebraska Medical Center ( Site 0047)
Omaha, Nebraska
Memorial Sloan Kettering Cancer Center Basking Ridge ( Site 0074)
Basking Ridge, New Jersey
Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0077)
Middletown, New Jersey
MSKCC-Bergen ( Site 0075)
Montvale, New Jersey
St. Peter's Hospital Cancer Care Center ( Site 0039)
Albany, New York
Memorial Sloan-Kettering Cancer Center at Commack ( Site 0076)
Commack, New York
Memorial Sloan Kettering Cancer Center Westchester ( Site 0079)
Harrison, New York
Memorial Sloan Kettering Cancer Center ( Site 0060)
New York, New York
Stony Brook University Medical Center - Cancer Center ( Site 0019)
Stony Brook, New York
Montefiore Einstein Center ( Site 0016)
The Bronx, New York
Memorial Sloan Kettering Cancer Center - Nassau ( Site 0078)
Uniondale, New York
White Plains Hospital Center for Cancer Care ( Site 0007)
White Plains, New York
Southwestern Regional Medical Center, Inc. ( Site 0054)
Tulsa, Oklahoma
Showing 40 of 227 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.